One third of patients with chronic obstructive pulmonary disease (COPD) feel they would receive better care if they had cancer, diabetes or heart disease, according to a new Chiesi-sponsored patient survey.
News
UK’s cell and gene therapy industry continues to strengthen
The UK’s cell and gene therapy industry has seen a 60% increase in manufacturing space in the last year, new research published by the Cell and Gene Therapy (CGT) Catapult has revealed.
GSK retains leading position on access to medicines list
GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Takeda gets European blessing for Shire acquisition
The European Commission has given its blessing for the proposed £46-billion acquisition of Shire by Takeda, paving the way for the deal’s completion.
Psychological therapy recovery rate surpasses 50% for the first time
More than half of patients who finished psychological therapy recovered in 2017-18, marking the first time the recovery rate has passed 50%.
European Commission approves Lilly’s Emgality for migraine
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
First Rare Disease Collaborative Network for refractory coeliac disease
Refractory coeliac disease, a deadly form of the autoimmune condition coeliac disease, has received its first dedicated support from NHS England, with the setting up of a Rare Disease Collaborative Network (RDCN) to accelerate research and treatment into this life threatening condition.
Mirati joins CR UK’s Stratified Medicine Programme
Mirati Therapeutics has joined Cancer Research UK’s Stratified Medicine Programme, bringing new investigational treatment options to eligible patients with advanced lung cancer.
GSK files Nucala for wider paediatric use
GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.
Public show ‘overwhelming’ support for reducing sugar, calories in food
A survey commissioned by Public Health England (PHE) has found that around nine in ten people support the government working with the food industry to make food healthier.
Merck, Pfizer’s Bavencio misses ovarian cancer trial endpoints
A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
Cardiff Uni and Takeda team up for new drug discovery collaboration
Cardiff University has formed a drug discovery collaboration with Takeda to identify new approaches for treating schizophrenia and other psychiatric disorders.
FDA expands scope of Novartis’ Promacta
US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy (IST).
Setback for AZ’ Imfinzi lung cancer combination
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
